Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).

Lucia TaramassoPaola TatarelliElena RicciGiordano MadedduBarbara MenzaghiNicola SquillaceGiuseppe Vittorio De SocioCanio MartinelliRoberto GulminettiPaolo MaggiGiancarlo OrofinoFrancesca VichiAntonio Di BiagioPaolo Bonfantinull null

Published in: BMC infectious diseases (2018)

In SCOLTA, all switches from PI/r regimens gave advantages on lipid profile, while stopping EFV had consistently favorable lipid effects only if replaced by RPV.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
physical activity
fatty acid